{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:47:07Z","timestamp":1791424027883,"version":"4.3.3"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T00:00:00Z","timestamp":1275868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1472-6963-10-153","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T06:16:25Z","timestamp":1275977785000},"source":"Crossref","is-referenced-by-count":187,"title":["Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers"],"prefix":"10.1186","volume":"10","author":[{"given":"Jakub","family":"Adamski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Godman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ofierska-Sujkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142awa","family":"Osi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Wendykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ott","family":"Laius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Kalaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Garuolien\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Haycox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Garattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars L","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,7]]},"reference":[{"key":"1290_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMp0804261","volume":"359","author":"T Lee","year":"2008","unstructured":"Lee T, Emanuel E: Tier 4 drugs and the fraying of the social compact. NEJM. 2008, 359: 333-5. 10.1056\/NEJMp0804261.","journal-title":"NEJM"},{"key":"1290_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2165\/00019053-200826070-00001","volume":"26","author":"B Wettermark","year":"2008","unstructured":"Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V: Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008, 26: 537-50. 10.2165\/00019053-200826070-00001.","journal-title":"Pharmacoeconomics"},{"key":"1290_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.healthpol.2007.08.005","volume":"85","author":"L Garattini","year":"2008","unstructured":"Garattini L, Motterlini N, Cornago D: Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. Health Policy. 2008, 85: 305-13. 10.1016\/j.healthpol.2007.08.005.","journal-title":"Health Policy"},{"key":"1290_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2009.1409","volume":"302","author":"F Clement","year":"2009","unstructured":"Clement F, Harris A, Li JJ, Yong K, Lee K, Manns BJ: Using effectiveness and cost-effectiveness to make drug coverage decisions - a comparison of Britain, Australia and Canada. JAMA. 2009, 302: 1437-43. 10.1001\/jama.2009.1409.","journal-title":"JAMA"},{"key":"1290_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/annonc\/mdn603","volume":"20","author":"C McCabe","year":"2009","unstructured":"McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, J\u00f6nsson B, Kallem K-J, Newling D, Nussler V, Paschen B, de Wilde R, Wilking N, Teale C, Zwierzina H: Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Annals of Oncology. 2009, 20: 403-12. 10.1093\/annonc\/mdn603.","journal-title":"Annals of Oncology"},{"key":"1290_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00228-008-0537-z","volume":"64","author":"S Garattini","year":"2008","unstructured":"Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson L: Enhancing the rational use of new medicines across European healthcare systems - A Position Paper. Eur Jn Clinical Pharmacology. 2008, 64: 1137-8. 10.1007\/s00228-008-0537-z.","journal-title":"Eur Jn Clinical Pharmacology"},{"key":"1290_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00019053-200826070-00002","volume":"26","author":"J Cook","year":"2008","unstructured":"Cook J, Vernon J, Mannin R: Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2008, 26: 551-6. 10.2165\/00019053-200826070-00002.","journal-title":"Pharmacoeconomics"},{"key":"1290_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/14737167.9.1.65","volume":"9","author":"B Godman","year":"2009","unstructured":"Godman B, Wettermark B, Hoffman M, Andersson K, Haycox A, Gustafsson LL: Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev Pharmacoeconomics Outcomes Res. 2009, 9: 65-83. 10.1586\/14737167.9.1.65.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"1290_CR9","first-page":"29","volume-title":"How much good do new medicines do? Basic & Clin Pharm & Toxicology","author":"A Walker","year":"2009","unstructured":"Walker A, Booth C, Brown A, Paterson K: How much good do new medicines do? Basic & Clin Pharm & Toxicology. 2009, 105 (Suppl 1): 29."},{"key":"1290_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/11530850-000000000-00000","volume":"28","author":"C McCabe","year":"2010","unstructured":"McCabe C, Stafinski T, Edlin R, Menon D: Access with evidence development schemes - a framework for description and evaluation. Pharmacoeconomics. 2010, 28: 143-52. 10.2165\/11530850-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"1290_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1586\/14737167.8.4.357","volume":"8","author":"B Godman","year":"2008","unstructured":"Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Weininger P: Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomcis Outcomes Res. 2008, 8: 357-71. 10.1586\/14737167.8.4.357.","journal-title":"Expert Rev. Pharmacoeconomcis Outcomes Res"},{"key":"1290_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00019053-200826020-00001","volume":"26","author":"B Godman","year":"2008","unstructured":"Godman B, Haycox A, Schwabe U, Joppi R, Garattini S: Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. PharmacoEconomics. 2008, 26: 91-8. 10.2165\/00019053-200826020-00001.","journal-title":"PharmacoEconomics"},{"key":"1290_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF03256162","volume":"8","author":"C Sermet","year":"2010","unstructured":"Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP: Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Applied Health Economics and Health Policy. 2010, 8: 7-24.","journal-title":"Applied Health Economics and Health Policy"},{"key":"1290_CR14","first-page":"18","volume":"14","author":"E Seeley","year":"2008","unstructured":"Seeley E, Kanavos P: Generic medicines from a societal perspective: Savings for healthcare systems?. Eurohealth. 2008, 14: 18-22.","journal-title":"Eurohealth"},{"key":"1290_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200927050-00010","volume":"27","author":"B Godman","year":"2009","unstructured":"Godman B, Schwabe U, Selke G, Wettermark B: Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of Proton Pump Inhibitors and lipid-lowering drugs. Pharmacoeconomics. 2009, 27: 1-4. 10.2165\/00019053-200927050-00010.","journal-title":"Pharmacoeconomics"},{"key":"1290_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1586\/erp.09.43","volume":"9","author":"B Godman","year":"2009","unstructured":"Godman B, Burkhardt T, Bucsics A, Wettermark B, Weininger P: Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev Pharmacoeconomcis and Outcomes Research. 2009, 9: 475-84. 10.1586\/erp.09.43.","journal-title":"Expert Rev Pharmacoeconomcis and Outcomes Research"},{"key":"1290_CR17","unstructured":"AIFA - Italian Medicines Agency: Working Group on Innovative Drugs. Criteria for Ranking Therapeutic Innovation of New Drugs and Elements for Supplementing the Dossier for Admission to the Reimbursement System (document approved by the AIFACTS on July 10, 2007) (accessed 3 March 2010), [ http:\/\/www.agenziafarmaco.it\/allegati\/integral_document.pdf ]"},{"key":"1290_CR18","volume-title":"Annexe K: International survey of pharmaceutical pricing and reimbursement schemes","author":"Office of Fair Trading (UK)","year":"2007","unstructured":"Office of Fair Trading (UK): The pharmaceutical price regulation system: an OFT study. Annexe K: International survey of pharmaceutical pricing and reimbursement schemes. 2007, London: The Office of Fair Trading, [online] [Accessed 3 March 2010], [ http:\/\/www.oft.gov.uk\/shared_oft\/reports\/comp_policy\/oft885k.pdf ]"},{"key":"1290_CR19","first-page":"224","volume-title":"IMS Pharma Pricing & Reimbursement","author":"Anon","year":"2007","unstructured":"Anon: Innovative approaches to pricing. IMS Pharma Pricing & Reimbursement. 2007, 224-227. (Accessed 3 March 2010), [ http:\/\/www.imshealth.com\/deployedfiles\/imshealth\/Global\/Content\/StaticFile\/Are_Traditional_Pricing_Models_Thing_of_Past.pdf ]"},{"key":"1290_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/11531410-000000000-00000","volume":"28","author":"A Briggs","year":"2010","unstructured":"Briggs A, Ritchie K, Fenwick E, Chalikidou K, Littlejohns P: Access with evidence development in the UK - past experience, current initiatives and future potential. Pharmacoeconomics. 2010, 28: 163-70. 10.2165\/11531410-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"1290_CR21","volume-title":"Roche plans to address cost of Avastin in Europe","author":"B Hirschler","year":"2008","unstructured":"Hirschler B: Roche plans to address cost of Avastin in Europe. 2008, (Accessed 3 March 2010), [ http:\/\/uk.reuters.com\/article\/idUKL1834800720070418 ]"},{"key":"1290_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-006-0386-6","volume":"7","author":"G de Pourville","year":"2006","unstructured":"de Pourville G: Risk-sharing arrangements for innovative drugs. A new solution to old problems. Eur J Health Econ. 2006, 7: 155-7. 10.1007\/s10198-006-0386-6.","journal-title":"Eur J Health Econ"},{"key":"1290_CR23","volume-title":"Cancer drugs costing \u00a350 billion will crush the NHS, says expert","author":"Anon","year":"2008","unstructured":"Anon: Cancer drugs costing \u00a350 billion will crush the NHS, says expert. 2008, (Accessed 3 March 2010), [ http:\/\/www.dailymail.co.uk\/health\/article-1053628\/Cancer-drugs-costing-50billion-crush-NHS-says-expert.html ]"},{"key":"1290_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/annonc\/mdn564","volume":"19","author":"A Jirillo","year":"2008","unstructured":"Jirillo A, Vascon F, Giacobbo M: Bevacizumab in advanced cancer, too much or too little?. Annals of Oncology. 2008, 19: 1817-8. 10.1093\/annonc\/mdn564.","journal-title":"Annals of Oncology"},{"key":"1290_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2008.15","volume":"83","author":"A Breckenridge","year":"2008","unstructured":"Breckenridge A, Walley T: Risk sharing and payment by results. Clin Pharmacol and Therapeutics. 2008, 83: 666-7. 10.1038\/clpt.2008.15.","journal-title":"Clin Pharmacol and Therapeutics"},{"key":"1290_CR26","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1136\/bmj.330.7502.1262","volume":"330","author":"C M\u00f8ldrup","year":"2005","unstructured":"M\u00f8ldrup C: No cure, no pay. BMJ. 2005, 330: 1262-4. 10.1136\/bmj.330.7502.1262.","journal-title":"BMJ"},{"key":"1290_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/bmj.326.7391.707","volume":"326","author":"S Chapman","year":"2003","unstructured":"Chapman S, Reeve E, Rajaratnam G, Neary R: Setting up an outcomes guarantee for pharmaceuticals: New approach to risk sharing in primary care. BMJ. 2003, 326: 707-9. 10.1136\/bmj.326.7391.707.","journal-title":"BMJ"},{"key":"1290_CR28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/20786204.2008.10873741","volume":"50","author":"C Carapinha","year":"2008","unstructured":"Carapinha C: Setting the stage for risk-sharing agreements: International experiences and outcomes-based reimbursement. SA Fam Pract. 2008, 50: 62-5.","journal-title":"SA Fam Pract"},{"key":"1290_CR29","unstructured":"NICE draft recommendation on the use of drugs for renal cancer. 2009\/009. [Accessed 3 March 2010], [ http:\/\/www.nice.org.uk\/media\/420\/AD\/2009009DraftNICEGuidanceDrugsRenalCancerv2.pdf ]"},{"key":"1290_CR30","volume-title":"Final NICE Kidney Cancer Guidance Recommends sunitinib","author":"Medical News Today","year":"2009","unstructured":"Medical News Today: Final NICE Kidney Cancer Guidance Recommends sunitinib. 2009, [Accessed 3 March 2010], [ http:\/\/www.medicalnewstoday.com\/articles\/143681.php ]"},{"key":"1290_CR31","volume-title":"Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy","author":"NICE","year":"2009","unstructured":"NICE: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. 2009, [Accessed 3 March 2010], [ http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA171GuidanceWord.doc ]"},{"key":"1290_CR32","volume-title":"UK's NICE approves lenalidomide in relapsed multiple myeloma","author":"HemOnc today","year":"2009","unstructured":"HemOnc today: UK's NICE approves lenalidomide in relapsed multiple myeloma. 2009, [Accessed 3 March 2010], [ http:\/\/www.hemonctoday.com\/article.aspx?rid=41000 ]"},{"key":"1290_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1071\/AH090192","volume":"33","author":"J Robertson","year":"2009","unstructured":"Robertson J, Walkom E, Henry D: Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Aust Health Rev. 2009, 33: 192-9. 10.1071\/AH090192.","journal-title":"Aust Health Rev"},{"key":"1290_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11530820-000000000-00000","volume":"28","author":"T Stafinski","year":"2010","unstructured":"Stafinski T, McCabe C, Menon D: Funding the unfundable - mechanisms for managing uncertainty in decisions on the introduction o new and innovative technologies into healthcare systems. Pharmacoeconomics. 2010, 28: 113-42. 10.2165\/11530820-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"1290_CR35","volume-title":"New UK PPRS includes 3.9% price cut, flexible pricing and generic substitution","author":"L Taylor","year":"2008","unstructured":"Taylor L: New UK PPRS includes 3.9% price cut, flexible pricing and generic substitution. 2008, Accessed 3 March 2010), [ http:\/\/www.eatg.org\/eatg\/Global-HIV-News\/Access-to-treatment\/New-UK-PPRS-includes-3.9-price-cut-flexible-pricing-and-generic-substitution ]"},{"key":"1290_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/11314080-000000000-00000","volume":"28","author":"A Towse","year":"2010","unstructured":"Towse A, Garrison L: Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk sharing agreements for innovative medical products. Pharmacoeconomics. 2010, 28: 93-102. 10.2165\/11314080-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"1290_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bmj.39491.469005.94","volume":"336","author":"A Jack","year":"2008","unstructured":"Jack A: Balancing Big Pharma's books. BMJ. 2008, 336: 418-9. 10.1136\/bmj.39491.469005.94.","journal-title":"BMJ"},{"key":"1290_CR38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/bmj.39008.624051.BE","volume":"333","author":"A Barrett","year":"2006","unstructured":"Barrett A, Riques T, Small M, Smith R: How much will Herceptin really cost?. BMJ. 2006, 333: 1118-20. 10.1136\/bmj.39008.624051.BE.","journal-title":"BMJ"},{"key":"1290_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/11531050-000000000-00000","volume":"28","author":"P Mohr","year":"2010","unstructured":"Mohr P, Tunis S: Access with evidence development - the US experience. Pharmaceoeconomics. 2010, 28: 153-62. 10.2165\/11531050-000000000-00000.","journal-title":"Pharmaceoeconomics"},{"key":"1290_CR40","doi-asserted-by":"crossref","unstructured":"Leader. Looking beyond the headlines. The Lancet Oncology. 2007, 8: 561-10.1016\/S1470-2045(07)70178-X.","DOI":"10.1016\/S1470-2045(07)70178-X"},{"key":"1290_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1470-2045(09)70402-4","volume":"11","author":"S Williamson","year":"2010","unstructured":"Williamson S: Patient access schemes for high-cost cancer medicines. Lancet. 2010, 11: 111-2. 10.1016\/S1470-2045(09)70402-4.","journal-title":"Lancet"},{"key":"1290_CR42","volume-title":"Pharmaceutical policies: effects of financial incentives for prescribers (Review)","author":"H Sturm","year":"2007","unstructured":"Sturm H, Austvoll-Dahlgren A, Aaserud M, et al: Pharmaceutical policies: effects of financial incentives for prescribers (Review). Cochrane database of Systematic Reviews. 2007, Art No.: CD006731 DOI: 10.1002\/14651858.CD006731, 3"},{"key":"1290_CR43","volume-title":"Pharmaceutical Pricing and Reimbursement Information, Belgium","author":"A de Swaef","year":"2007","unstructured":"de Swaef A, Antonissen Y: Pharmaceutical Pricing and Reimbursement Information, Belgium. 2007, (Accessed 3 March 2010), [ http:\/\/ppri.oebig.at\/Downloads\/Results\/Belgium_PPRI_2007.pdf ]"},{"key":"1290_CR44","volume-title":"A study funded by DG Enterprise and Industry of the European Commission","author":"J Esp\u00edn","year":"2007","unstructured":"Esp\u00edn J, Rovira J: Analysis of differences and commonalities in pricing and reimbursement systems in Europe. A study funded by DG Enterprise and Industry of the European Commission. 2007, (Accessed 3 March 2010), [ http:\/\/kce.docressources.info\/opac\/index.php?lvl=notice_display&id=912 ]"},{"key":"1290_CR45","volume-title":"Pharmaceutical Pricing and Reimbursement Information, ESTONIA","author":"K Pudersell","year":"2007","unstructured":"Pudersell K, Vetka A, Rootslane L, Mari Mathiesen, et al: Pharmaceutical Pricing and Reimbursement Information, ESTONIA. 2007, (Accessed 3 March 2010), [ http:\/\/ppri.oebig.at\/Downloads\/Results\/Estonia_PPRI_2007.pdf ]"},{"key":"1290_CR46","unstructured":"Health Systems in Transition. Estonia Health. 2008, 10 (1): (Accessed 3 March 2010), [ http:\/\/www.hpm.org\/Downloads\/reports\/HiT_reports\/Hit_Estonia_2008.pdf ]"},{"key":"1290_CR47","volume-title":"Working paper (DT number 16)","author":"N Grandfils","year":"2008","unstructured":"Grandfils N: Drug price setting and regulation in France. Working paper (DT number 16). 2008, (accessed 3 March 2010), [ http:\/\/www.irdes.fr\/EspaceAnglais\/Publications\/WorkingPapers\/DT16DrugPriceSettingRegulationFrance.pdf ]"},{"key":"1290_CR48","volume-title":"Healthcare Products Pricing Committee Annual Report","author":"Comite Economique Des Produits De Sante","year":"2008","unstructured":"Comite Economique Des Produits De Sante: Healthcare Products Pricing Committee Annual Report. 2008, [Accessed 3 March 2010], [ http:\/\/www.sante.gouv.fr\/ceps\/doc\/rapport_activite_ceps_2008_anglais.pdf ]"},{"key":"1290_CR49","doi-asserted-by":"crossref","unstructured":"European Legal Developments Bulletin: 2007, 19 (2): 17-19. spring","DOI":"10.1016\/S1464-2859(07)70076-7"},{"key":"1290_CR50","volume-title":"Pharmaceutical Pricing and Reimbursement Information, HUNGARY","author":"T Kov\u00e1cs","year":"2007","unstructured":"Kov\u00e1cs T, R\u00f3zsa P, Szigeti S, et al: Pharmaceutical Pricing and Reimbursement Information, HUNGARY. 2007, (Accessed 3 March 2010), [ http:\/\/ppri.oebig.at\/Downloads\/Results\/Hungary_PPRI_2007.pdf ]"},{"key":"1290_CR51","volume-title":"Pharmaceutical risk-sharing and conditional reimbursement in Italy","author":"P Folino Gallo","year":"2008","unstructured":"Folino Gallo P, Deambrosis P: Pharmaceutical risk-sharing and conditional reimbursement in Italy. 2008, Krakow, (Accessed 3 March 2010), [ http:\/\/www.ceestahc.org\/pliki\/symp2008\/gallo.pdf ]"},{"key":"1290_CR52","volume-title":"Health Systems in Transition","author":"P Barros","year":"2007","unstructured":"Barros P, de Almeida Sim\u00f5es J: Health Systems in Transition. 2007, 9 (5): Portugal: Health system review 2007 (Accessed 3 March 2010)"},{"key":"1290_CR53","volume-title":"Pharmaceutical Pricing Reimbursement Information, Portugal","author":"I Teixeira","year":"2008","unstructured":"Teixeira I, Vieira I: Pharmaceutical Pricing Reimbursement Information, Portugal. 2008, (Accessed 3 March 2010), [ http:\/\/ppri.oebig.at\/Downloads\/Results\/Portugal_PPRI_2008.pdf ]"},{"key":"1290_CR54","unstructured":"Cetuximab for first line treatment of metastatic colorectal cancer (MCRC). 2009, [Accessed 3 March 2010], [ http:\/\/www.nice.org.uk\/nicemedia\/pdf\/ColorectalCancerCetuxamibACD2ManPAS.pdf ]"},{"key":"1290_CR55","unstructured":"NICE draft recommendation on the use of drugs for renal cancer. 2009\/009. [Accessed 29 July 09], [ http:\/\/www.nice.org.uk\/media\/420\/AD\/2009009DraftNICEGuidanceDrugsRenalCancerv2.pdf ]"},{"key":"1290_CR56","volume-title":"Final NICE Kidney Cancer Guidance Recommends sunitinib","author":"Medical News Today","year":"2009","unstructured":"Medical News Today: Final NICE Kidney Cancer Guidance Recommends sunitinib. 2009, [Accessed 3 March 2010], [ http:\/\/www.medicalnewstoday.com\/articles\/143681.php ]"},{"key":"1290_CR57","volume-title":"Scottish Medicines Consortium - cetuximab, 100 mg\/20 ml and 500 mg\/100 ml solution for intravenous infusion","author":"Anon","year":"2010","unstructured":"Anon: Scottish Medicines Consortium - cetuximab, 100 mg\/20 ml and 500 mg\/100 ml solution for intravenous infusion. 2010, (Accessed 3 March 2010), [ http:\/\/www.scottishmedicines.org.uk\/files\/cetuximab%20Erbitux%20RESUBMISSION%20FINAL%20January%202010%20for%20website.pdf ]"},{"key":"1290_CR58","volume-title":"Scrip News","author":"Anon","year":"2008","unstructured":"Anon: Final NICE Guidance Recommends Lucentis(R) (Ranibizumab) For Wet AMD in UK. Scrip News. 2008, (Accessed 03 Jan 2010), [ http:\/\/www.scripnews.com\/news\/nice-confirms-lucentis-choice-for-wet-amd-526 ]"},{"key":"1290_CR59","unstructured":"NICE: Costing statement: Ustekinumab for the treatment of adults with moderate to severe psoriasis. [Accessed 3 March 2010], [ http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA180UstekinumabForTheTreatmentOfPsoriasisCostingStatement.pdf ]"},{"key":"1290_CR60","volume-title":"Scottish Medicines Consortium - ustekinumab 45 mg solution for injection","author":"Anon","year":"2010","unstructured":"Anon: Scottish Medicines Consortium - ustekinumab 45 mg solution for injection. 2010, (Accessed 28 February 2010), [ http:\/\/www.scottishmedicines.org.uk\/files\/ustekinumab%20Stelara%20FINAL%20January%202010%20Amended%2004.02.10%20for%20website.pdf ]"},{"key":"1290_CR61","volume-title":"Top of The Cancer Market?","author":"M Herper","year":"2006","unstructured":"Herper M: Top of The Cancer Market?. 2006, (Accessed 3 March 2010), [ http:\/\/www.forbes.com\/2006\/10\/12\/cancer-drug-pricing-biz-cz_mh_1012drugs.html ]"},{"key":"1290_CR62","volume-title":"Genentech Caps Cost of Cancer Drug for Some Patients","author":"A Pollack","year":"2006","unstructured":"Pollack A: Genentech Caps Cost of Cancer Drug for Some Patients. 2006, (Accessed 29 June 09), [ http:\/\/www.consumerwatchdog.org\/patients\/articles\/?storyId=14384&bIndex=0 ]"},{"key":"1290_CR63","volume-title":"Injectable claim edit (maximum dosage drug policy)","author":"United Healthcare","year":"2008","unstructured":"United Healthcare: Injectable claim edit (maximum dosage drug policy). 2008, (Accessed 3 March 2010), [ https:\/\/www.unitedhealthcareonline.com\/ccmcontent\/ProviderII\/UHC\/en-US\/Assets\/ProviderStaticFiles\/ProviderStaticFilesPdf\/Clinician%20Resources\/Cancer%20Oncology\/Injectable%20Drug%20March08%20NB%20Article.pdf ]"},{"key":"1290_CR64","volume-title":"Generic Biotech Products: Are the Floodgates Open? At Whose Expense?, Biotech Business","author":"Anon","year":"2008","unstructured":"Anon: Generic Biotech Products: Are the Floodgates Open? At Whose Expense?, Biotech Business. 2008, (3 March 2010), [ http:\/\/www.biotechnologyhealthcare.com\/journal\/fulltext\/3\/4\/BH0304022.pdf ]"},{"key":"1290_CR65","unstructured":"Amgen: Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients. (Accessed 3 March 2010), [ http:\/\/findarticles.com\/p\/articles\/mi_m0EIN\/is_2006_Sept_27\/ai_n16836635\/ ]"},{"key":"1290_CR66","unstructured":"Sanofi-Aventis: Sculptra\u2122 Patient Access Program. [Accessed 3 March 2010], [ http:\/\/www.pparx.org\/resources\/2008-05-19.SanofiAventis.Sculptra_Patient_Access_Program.3008.pdf ]"},{"key":"1290_CR67","unstructured":"Gilead: Need Help Paying for TRUVADA?. [Accessed 3 March 2010], [ http:\/\/www.truvada.com\/pat400_paying_for_your_hiv_meds.aspx ]"},{"key":"1290_CR68","volume-title":"Free Prescription Drugs to Unemployed Courtesy of Pfizer, Inc","author":"Carly Hart","year":"2009","unstructured":"Hart Carly: Free Prescription Drugs to Unemployed Courtesy of Pfizer, Inc. 2009, [ http:\/\/www.associatedcontent.com\/article\/1747496\/free_prescription_drugs_to_unemployed.html ]"},{"key":"1290_CR69","unstructured":"Anderson P: Clozapine comes with money-back offer. (accessed 3 March 2010), [ http:\/\/www.mentalhealth.com\/mag1\/p51-cloz.html ]"},{"key":"1290_CR70","doi-asserted-by":"crossref","unstructured":"Fuschillo C, Ascoli F, Franzese G, Campana F, Cello C, Galdi M, La Pia S, Cetrangolo C: Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. Arch Gerontol Geriatr Suppl. 2004, 187-94. 10.1016\/j.archger.2004.04.026. 9","DOI":"10.1016\/j.archger.2004.04.026"},{"key":"1290_CR71","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/BF03337721","volume":"17","author":"G Bellelli","year":"2005","unstructured":"Bellelli G, Lucchi E, Minicuci N, Rozzini L, Bianchetti A, Padovani A, Trabucchi M: Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the \"real world\" (CRONOS project): a 36-week follow-up study. Aging Clin Exp Res. 2005, 17: 54-61.","journal-title":"Aging Clin Exp Res"},{"key":"1290_CR72","unstructured":"Anon NICE: Final appraisal determination bortezomib monotherapy for relapsed multiple myeloma. (accessed 3 March 2010), [ http:\/\/www.nice.org.uk\/nicemedia\/pdf\/FAD.pdf ]"},{"key":"1290_CR73","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMp078204","volume":"357","author":"A Garber","year":"2007","unstructured":"Garber A, McCellan M: Satisfaction guaranteed - 'Payment by results' for biologic agents. NEJM. 2007, 357: 1575-7. 10.1056\/NEJMp078204.","journal-title":"NEJM"},{"key":"1290_CR74","first-page":"205","volume":"11","author":"S Chapman","year":"2004","unstructured":"Chapman S, Reeve E, Rajaratnam G, Neary R: Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care. Br J cardiol. 2004, 11: 205-10.","journal-title":"Br J cardiol"},{"key":"1290_CR75","volume-title":"The Pharmaceutical Price regulation System - An OFT study","author":"Office of Fair Trading (UK)","year":"2007","unstructured":"Office of Fair Trading (UK): The Pharmaceutical Price regulation System - An OFT study. 2007, (accessed 3 March 2010), [ http:\/\/www.oft.gov.uk ]"},{"key":"1290_CR76","doi-asserted-by":"publisher","first-page":"b4677","DOI":"10.1136\/bmj.b4677","volume":"339","author":"M Boggild","year":"2009","unstructured":"Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenezer T, Dobson C, Gray R: Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009, 339: b4677-10.1136\/bmj.b4677.","journal-title":"BMJ"},{"key":"1290_CR77","first-page":"239","volume-title":"No cure, no pay: an acceptable way of financing fertility treatments? Health Policy","author":"G Haan","year":"1989","unstructured":"Haan G, Rutten F: No cure, no pay: an acceptable way of financing fertility treatments? Health Policy. 1989, 13: 239-49."},{"key":"1290_CR78","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1742-1241.2007.01630.x","volume":"62","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Benedict A, Muszabek N, Keskinaslan A, Khan Z: The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008, 62: 76-87. 10.1111\/j.1742-1241.2007.01630.x.","journal-title":"Int J Clin Pract"},{"key":"1290_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03256137","volume":"7","author":"B Wettermark","year":"2009","unstructured":"Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F: Soft Regulations in Pharmaceutical Policymaking: An Overview of Current Approaches and their Consequences. Appl Econ Health Policy. 2009, 7: 1-11.","journal-title":"Appl Econ Health Policy"},{"key":"1290_CR80","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S0140-6736(07)61494-9","volume":"370","author":"R Hyde","year":"2007","unstructured":"Hyde R: Doctors to pay for patients' medicine in Germany. Lancet. 2007, 370: 1118-10.1016\/S0140-6736(07)61494-9.","journal-title":"Lancet"},{"key":"1290_CR81","unstructured":"Yack D: Adherence to long-term therapies - Evidence for action. WHO 2003 - WHO\/MNC\/03.01. (Accessed 3 March 2010), [ http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_introduction.pdf ]"},{"key":"1290_CR82","volume-title":"NCCSDO","author":"R Horne","year":"2005","unstructured":"Horne R, Weinman J, Barber N, et al: Concordance, adherence and compliance in medicine taking. NCCSDO. 2005, (Accessed 3 March 2010), [ http:\/\/www.npci.org.uk\/adherence_to_medicines\/atm\/intro\/resources\/library_horne_final_report.pdf ]"},{"key":"1290_CR83","volume-title":"Eur J Clin Pharmacol","author":"S Perreault","year":"2009","unstructured":"Perreault S, Dragomir A, Blais L, Berrard A, Lalonde L, White M, Pilon D: Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009, DOI 10.1007\/s00228-009-0673-0"},{"key":"1290_CR84","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/bmj.39281.615706.94","volume":"335","author":"S Garattini","year":"2007","unstructured":"Garattini S, Bertele' V: How can we regulate medicines better. BMJ. 2007, 335: 803-5. 10.1136\/bmj.39281.615706.94.","journal-title":"BMJ"},{"key":"1290_CR85","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.bjc.6602750","volume":"93","author":"G Apolone","year":"2005","unstructured":"Apolone G, Joppi R, Bertele V, Garattini S: Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer. 2005, 93: 504-9. 10.1038\/sj.bjc.6602750.","journal-title":"British Journal of Cancer"},{"key":"1290_CR86","volume-title":"Eur J Clin Pharmacol","author":"R Joppi","year":"2009","unstructured":"Joppi R, Dematte L, Menti AM, Pase D, Poggiani C, Mezzalira L: The Italian Horizon Scanning project. Eur J Clin Pharmacol. 2009, (published online - DOI 10.1007\/s00228-009-0666-z)"},{"key":"1290_CR87","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/bmj.39434.500185.25","volume":"336","author":"K Claxton","year":"2008","unstructured":"Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walke S, Sculpher M: Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ. 2008, 336: 252-4. 10.1136\/bmj.39434.500185.25.","journal-title":"BMJ"},{"key":"1290_CR88","first-page":"271","volume":"274","author":"S Pegler","year":"2005","unstructured":"Pegler S, Underhill J: Evaluating promotional material from industry: an evidence-based approach. Pharmaceutical Jn. 2005, 274: 271-4.","journal-title":"Pharmaceutical Jn"},{"key":"1290_CR89","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1586\/14737167.7.3.207","volume":"7","author":"T Walley","year":"2007","unstructured":"Walley T: Fair pricing for medicines in the UK. Expert Rev Pharmacoeconomics and Outcomes Res. 2007, 7: 207-9. 10.1586\/14737167.7.3.207.","journal-title":"Expert Rev Pharmacoeconomics and Outcomes Res"},{"key":"1290_CR90","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(07)60648-5","volume":"369","author":"D Webb","year":"2007","unstructured":"Webb D, Walker A: Value-based pricing of drugs in the UK. Lancet. 2007, 369: 1415-6. 10.1016\/S0140-6736(07)60648-5.","journal-title":"Lancet"},{"key":"1290_CR91","first-page":"1","volume-title":"Neuropsychotherapeutics in the UK; what has been the impact of NICE? CNS Drugs","author":"T Walley","year":"2004","unstructured":"Walley T: Neuropsychotherapeutics in the UK; what has been the impact of NICE? CNS Drugs. 2004, 18: 1-12."},{"key":"1290_CR92","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/00004479-200404000-00009","volume":"27","author":"M Duerden","year":"2004","unstructured":"Duerden M, Gogna N, Godman B, Eden K, Mallinson M: Current National Initiatives Policies to control drug costs in Europe: UK perspective. J Ambulatory Care Manage. 2004, 27: 132-8.","journal-title":"J Ambulatory Care Manage"},{"key":"1290_CR93","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/bmj.326.7385.388","volume":"326","author":"S Sudlow","year":"2003","unstructured":"Sudlow S, Counsel C: Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ. 2003, 326: 288-92. 10.1136\/bmj.326.7385.388.","journal-title":"BMJ"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-10-153\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-10-153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-10-153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-10-153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T13:29:50Z","timestamp":1591363790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-10-153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,7]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-10-153","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,7]]},"article-number":"153"}}